Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -151.57% is 49% below its 5-year average of -101.65%, around the middle of its 5-year range (-221.26%–-39.86%).
6.83% below its 12-month average of -141.88%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -39.21%.
RETURN ON ASSETS (ROA)
-151.57%
RETURN ON ASSETS (ROA) AVG TTM
-141.88%
RETURN ON ASSETS (ROA) AVG 3Y
-132.44%
RETURN ON ASSETS (ROA) AVG 5Y
-101.65%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.83%
CURRENT VS 3Y AVG
-14.44%
CURRENT VS 5Y AVG
-49.11%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 853 covered companies
CURRENT VS SECTOR MEDIAN
-370.13%
vs the sector median at left
Longeveron Inc.
Market Cap
$7.21M
Return on Assets (ROA)
-151.57%
TTM Avg
-141.88%
3Y Avg
-132.44%
5Y Avg
-101.65%
Market Cap
$7.29M
Return on Assets (ROA)
-457.62%
TTM Avg
-117.02%
3Y Avg
-190.78%
5Y Avg
-182.53%
Market Cap
$7.25M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
Market Cap
$7.13M
Return on Assets (ROA)
-106.57%
TTM Avg
-92.47%
3Y Avg
-315.20%
5Y Avg
-267.86%
Market Cap
$6.95M
Return on Assets (ROA)
-72.69%
TTM Avg
-49.83%
3Y Avg
-64.20%
5Y Avg
-63.36%
Market Cap
$7.07M
Return on Assets (ROA)
-95.26%
TTM Avg
-176.86%
3Y Avg
-120.19%
5Y Avg
-105.02%
Market Cap
$7.13M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$6.95M
Return on Assets (ROA)
-1082.20%
TTM Avg
-652.69%
3Y Avg
-445.69%
5Y Avg
-363.52%
Market Cap
$6.94M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Longeveron Inc. (LGVN) | $7.21M | -151.57% | -141.88% | -132.44% | -101.65% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.29M | -457.62% | -117.02% | -190.78% | -182.53% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -414.54% | -226.50% | -135.75% | -126.75% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.13M | -106.57% | -92.47% | -315.20% | -267.86% |
| Exicure, Inc. (XCUR)vs › | $6.95M | -72.69% | -49.83% | -64.20% | -63.36% |
| KALA BIO, Inc. (KALA)vs › | $7.07M | -95.26% | -176.86% | -120.19% | -105.02% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | -283.63% | -124.17% | -74.25% | -35.74% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.95M | -1082.20% | -652.69% | -445.69% | -363.52% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.94M | -71.23% | -61.08% | -51.04% | -61.11% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.84M | -206.32% | -53.14% | -33.03% | -33.03% |
ROA
-151.6%
ROE
-225.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -221.26% |
| 2024-12-31 | -62.50% |
| 2023-12-31 | -177.29% |
| 2022-12-31 | -68.71% |
| 2021-12-31 | -39.86% |
| 2020-12-31 | -40.27% |
| 2019-12-31 | -35.15% |
| 2018-12-31 | -60.23% |
